原发性系统性淀粉样变患者的临床特征和生存分析
被引量：1
摘要
系统性淀粉样变性包括一组疾病，其中原发性系统性淀粉样变（primarysystemiclight-chainamyloidosis，AL）最常见，占80％左右，国外报道其中位生存时间仅1—2年，国内尚无其生存分析的相关报道。我们对1998年1月至2008年3月收治的25例原发性系统性AL患者进行回顾性分析，探讨影响患者生存的预后因素。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2009年第11期772-774,共3页
Chinese Journal of Hematology
参考文献9
-
1Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med, 1997, 337: 898-909.
-
2Kyle RA, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 1995, 32: 45-59.
-
3Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL) : a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol, 2005, 79,319-328.
-
4颜绵生,孙艳虹,廖慧芳,姚少羽,冯品宁,潘锡龙.免疫固定技术在轻链型多发性骨髓瘤分型中的应用[J].实用医学杂志,2006,22(1):93-94. 被引量：6
-
5Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating immunoglobulin free light chains following chemotherapy. Br J Haematol, 2003, 122 : 78-84.
-
6Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med, 1998, 91 : 141-157.
-
7Osawa Y, Kawamura K, Kondo D, et al. Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary AL-type amyloidosis. Clin Exp Nephrol, 2004, 8: 127-133.
-
8Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in the treatment of AL amyloidosis. Br J Haematol, 2007, 140: 365- 377.
-
9Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med, 2004, 140: 85- 94.
二级参考文献6
-
1罗绍凯.提高多发性骨髓瘤的疗效[J].新医学,2004,35(7):396-397. 被引量：1
-
2REES J, OHRMUNDT J. The usefulness of quantifyuing kappa and lambda light chains [J]. Clin Chore, 1986,32(5):899.
-
3ROACH B M, MEINKE J S, SRIDBAR N. et al. Multiple narrow bands in urine protein eleetrophoresis [J]. Clin Chem, 1999, 45(5):716 -718.
-
4翟玉华,朱嘉芷,张惠玲,宿莉,陈文明,王清涛.血清免疫球蛋白轻链含量检测对M蛋白血症的诊断意义[J].临床血液学杂志,2000,13(4):177-178. 被引量：12
-
5沈霞.电泳技术的现状和发展[J].中华检验医学杂志,2001,24(5):263-265. 被引量：35
-
6丛秀丽,孙秀娟,钱林生.43例轻链型多发性骨髓瘤临床分析[J].白血病．淋巴瘤,2003,12(5):291-292. 被引量：8
共引文献5
-
1李畅,赵文静,耿红莲,仲人前,孔宪涛.22例轻链型多发性骨髓瘤实验室检查特征及轻链多聚体的鉴定[J].现代检验医学杂志,2008,23(5):57-59. 被引量：1
-
2王荷花,颜绵生,许多荣,童秀珍,陈文芳,李娟.心脏原发轻链型淀粉样变临床特点和生存分析[J].中国实用内科杂志,2009,29(11):1003-1005.
-
3颜绵生,喻雄文,廖慧芳.IgA型多发性骨髓瘤分型特征及其双M蛋白来源分析[J].实用医学杂志,2010,26(4):673-674. 被引量：5
-
4任菲菲,王越,刁波,刘华荆,薛燕南,刘莹.轻链型多发性骨髓瘤中血、尿轻链与M蛋白的相关性分析[J].华南国防医学杂志,2022,36(10):778-780. 被引量：1
-
5孙丹琦,周小飞,冯蒙蒙.纹理分析在鉴别多发性骨髓瘤轻链亚型中的运用[J].中国血液流变学杂志,2023,33(4):608-612.
同被引文献12
-
1Blad6 J, Samson D, Reeee D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol, 1998, 102: 1115-1123.
-
2Durie BG, Harousseau JL, Miguel JS, et al. International uniformresponse criteria for multiple myeloma. Leukemia, 2006, 20: 1467-1473.
-
3Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high- dose therapy and hematopoietic cell transplantation. Blood, 1998, 91 3518-3523.
-
4武永吉.多发性骨髓瘤//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235.
-
5Wadhera RK, Kyle RA, Larson DR, et al. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of un- determined significance in patients with multiple myeloma. Blood, 2011, 118: 2985-2987.
-
6Hovenga S, de Wolf JT, Guikema JE, et al. Autologons stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant, 2000, 25: 723-728.
-
7Niesvizky R, Jayabalan DS, [ clarithromycin ]/Revlimid Christos PJ, et al. BiRD (Biaxin [ lenalidomide ]/dexamethasone ) combination therapy results in sponse rates in treatment-naive Blood, 2008, 111:1101-1109. high complete- and overall-re- symptomatic multiple myeloma.
-
8Mark T, Jayabalan D, Coleman M, et al Atypical serum immu- nofixation patterns frequently emerge in immunomodulatory thera- py and are associated with a high degree of response in multiple myeloma. Br J Haematol, 2008,143:654-660.
-
9Gerritsen E J, Van To! M J, Van' t Veer MB, et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood, 1994, 84 : 4374-4352.
-
10Xiang Z, Cutler A J, Brownlie R J, et al. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immu- no1, 2007, 8 : 419-429.
二级引证文献3
-
1黄前川,张新华.多发性骨髓瘤干细胞移植术后伴异常蛋白带与疗效和预后的相关性[J].实用癌症杂志,2016,31(1):169-170. 被引量：4
-
2刘俊茹,李娟.《中国多发性骨髓瘤诊治指南（2017年修订）》疗效标准部分的解读[J].中华内科杂志,2017,56(11):800-803. 被引量：16
-
3曹莉,王莹,曹江,齐昆明,程海,朱锋,孙海英,闫志凌,桑威,李德鹏,李振宇,徐开林.寡克隆条带和(或)Ig同型转换对多发性骨髓瘤的疗效和预后评价的意义[J].临床血液学杂志,2022,35(9):639-644.
-
1盖晓波,李云良.系统性淀粉样变化[J].中华血液学杂志,1993,14(9):486-487.
-
2无,李明龙,张荣荣(整理).老年原发性系统性淀粉样变1例[J].中华老年多器官疾病杂志,2012,11(11):861-864.
-
3王玉昆,姬红岩,江培忠,刘杰.多发性骨髓瘤伴系统性淀粉样变的胸部X线表现:附2例报告[J].中国临床医学,2001,8(5):555-556.
-
4潘卫红,郑望苟,李娜萍.舌活检在原发性系统性淀粉样变性病诊断中的价值[J].华中科技大学学报（医学版）,2005,34(3):378-380. 被引量：3
-
5翟金月,孙俊芳.不典型发病系统性淀粉样变患者1例的护理[J].解放军护理杂志,2004,21(2):89-89.
-
6姜昆,王文鑫,刘佳玮,马东来.原发性系统性淀粉样变并发多发性骨髓瘤1例[J].中国麻风皮肤病杂志,2013,29(1):51-52. 被引量：1
-
7陈伟,李薇,熊琳,黎静宜,赵颖,王琳,冉玉平.原发性系统性淀粉样变病1例报告并文献复习[J].中国误诊学杂志,2006,6(4):607-609. 被引量：4
-
8刘莹,张辉,倪然,张筠.系统性淀粉样变26例临床分析[J].医药论坛杂志,2010,31(14):12-13. 被引量：1
-
9张虹,梅坚,李芹,林俊,和芳.系统性淀粉样变一例[J].中华风湿病学杂志,2005,9(9):575-575.
-
10赵卫华,尹瑶,姚奕斌,彭志刚.成人淀粉样变性85例临床分析[J].广西医科大学学报,2016,33(5):868-870. 被引量：6
